Benzinga | Oct 20, 2021 07:40AM EDT

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements In Its Broad Genome Editing Capabilities At The 2021 European Society Of Gene & Cell Therapy Annual Congress

* First preclinical data demonstrating Intellia's allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatments

* Demonstrated lipid nanoparticle-based delivery as a more efficient multiplex gene editing approach for engineered cell therapies as compared to electroporation

* Achieved durable production of normal human alpha-1 antitrypsin protein levels and reduction of endogenous disease-associated protein in non-human primates for the treatment of liver and/or lung manifestations of alpha-1 antitrypsin deficiency (AATD)

* Platform advances support acceleration of future drug development candidates from both Intellia's in vivo and ex vivo research portfolio